Jounce Therpeutc Common Stock

Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

25 Feb 2021 06:30:00 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Upcoming Investor Conferences in March

23 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021

18 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors

12 Feb 2021 08:00:00 By Nasdaq GlobeNewswire

Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors

13 Jan 2021 08:00:01 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Upcoming Investor Conferences in January

08 Jan 2021 08:00:00 By Nasdaq GlobeNewswire

Jounce Therapeutics Added to NASDAQ Biotechnology Index

16 Dec 2020 08:00:01 By Nasdaq GlobeNewswire

Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

25 Nov 2020 08:00:00 By Nasdaq GlobeNewswire

Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism

16 Nov 2020 08:00:01 By Nasdaq GlobeNewswire

Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting

11 Nov 2020 08:00:00 By Nasdaq GlobeNewswire

Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit

09 Nov 2020 08:00:01 By Nasdaq GlobeNewswire

Jounce Therapeutics Reports Third Quarter 2020 Financial Results

06 Nov 2020 07:00:00 By Nasdaq GlobeNewswire

Jounce Therapeutics Announces Update on Vopratelimab Program

02 Nov 2020 07:00:01 By Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020

30 Oct 2020 08:00:10 By Nasdaq GlobeNewswire

Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September

02 Sep 2020 16:01:10 By Nasdaq GlobeNewswire

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

01 Sep 2020 08:30:10 By Nasdaq GlobeNewswire

Jounce Therapeutics Reports Second Quarter 2020 Financial Results

07 Aug 2020 06:30:10 By Nasdaq GlobeNewswire

Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Conference 2020

04 Aug 2020 08:00:11 By Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Friday, August 7, 2020

31 Jul 2020 08:00:10 By Nasdaq GlobeNewswire

Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting

22 Jun 2020 09:00:10 By Nasdaq GlobeNewswire